Cargando…

Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade

Anti-cancer drug design has been acknowledged as a complicated, expensive, time-consuming, and challenging task. How to reduce the research costs and speed up the development process of anti-cancer drug designs has become a challenging and urgent question for the pharmaceutical industry. Computer-ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Liuying, Song, Yongzhen, Wang, Hesong, Zhang, Xuan, Wang, Meng, He, Jia, Li, Shuang, Zhang, Liuchao, Li, Kang, Cao, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963982/
https://www.ncbi.nlm.nih.gov/pubmed/37259400
http://dx.doi.org/10.3390/ph16020253
_version_ 1784896389970395136
author Wang, Liuying
Song, Yongzhen
Wang, Hesong
Zhang, Xuan
Wang, Meng
He, Jia
Li, Shuang
Zhang, Liuchao
Li, Kang
Cao, Lei
author_facet Wang, Liuying
Song, Yongzhen
Wang, Hesong
Zhang, Xuan
Wang, Meng
He, Jia
Li, Shuang
Zhang, Liuchao
Li, Kang
Cao, Lei
author_sort Wang, Liuying
collection PubMed
description Anti-cancer drug design has been acknowledged as a complicated, expensive, time-consuming, and challenging task. How to reduce the research costs and speed up the development process of anti-cancer drug designs has become a challenging and urgent question for the pharmaceutical industry. Computer-aided drug design methods have played a major role in the development of cancer treatments for over three decades. Recently, artificial intelligence has emerged as a powerful and promising technology for faster, cheaper, and more effective anti-cancer drug designs. This study is a narrative review that reviews a wide range of applications of artificial intelligence-based methods in anti-cancer drug design. We further clarify the fundamental principles of these methods, along with their advantages and disadvantages. Furthermore, we collate a large number of databases, including the omics database, the epigenomics database, the chemical compound database, and drug databases. Other researchers can consider them and adapt them to their own requirements.
format Online
Article
Text
id pubmed-9963982
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99639822023-02-26 Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade Wang, Liuying Song, Yongzhen Wang, Hesong Zhang, Xuan Wang, Meng He, Jia Li, Shuang Zhang, Liuchao Li, Kang Cao, Lei Pharmaceuticals (Basel) Review Anti-cancer drug design has been acknowledged as a complicated, expensive, time-consuming, and challenging task. How to reduce the research costs and speed up the development process of anti-cancer drug designs has become a challenging and urgent question for the pharmaceutical industry. Computer-aided drug design methods have played a major role in the development of cancer treatments for over three decades. Recently, artificial intelligence has emerged as a powerful and promising technology for faster, cheaper, and more effective anti-cancer drug designs. This study is a narrative review that reviews a wide range of applications of artificial intelligence-based methods in anti-cancer drug design. We further clarify the fundamental principles of these methods, along with their advantages and disadvantages. Furthermore, we collate a large number of databases, including the omics database, the epigenomics database, the chemical compound database, and drug databases. Other researchers can consider them and adapt them to their own requirements. MDPI 2023-02-07 /pmc/articles/PMC9963982/ /pubmed/37259400 http://dx.doi.org/10.3390/ph16020253 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wang, Liuying
Song, Yongzhen
Wang, Hesong
Zhang, Xuan
Wang, Meng
He, Jia
Li, Shuang
Zhang, Liuchao
Li, Kang
Cao, Lei
Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade
title Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade
title_full Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade
title_fullStr Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade
title_full_unstemmed Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade
title_short Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade
title_sort advances of artificial intelligence in anti-cancer drug design: a review of the past decade
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963982/
https://www.ncbi.nlm.nih.gov/pubmed/37259400
http://dx.doi.org/10.3390/ph16020253
work_keys_str_mv AT wangliuying advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade
AT songyongzhen advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade
AT wanghesong advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade
AT zhangxuan advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade
AT wangmeng advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade
AT hejia advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade
AT lishuang advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade
AT zhangliuchao advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade
AT likang advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade
AT caolei advancesofartificialintelligenceinanticancerdrugdesignareviewofthepastdecade